Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer | Zendy

Keisuke Enomoto | Zendy; Xuguang Zhu | Zendy; SunMi Park | Zendy; Li Zhao | Zendy; Yuelin J. Zhu | Zendy; Mark C. Willingham | Zendy; Jun Qi | Zendy; John A. Copland | Zendy; Paul S. Meltzer | Zendy; Sheue-yann Cheng | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer

Author(s) -

Keisuke Enomoto,

Xuguang Zhu,

SunMi Park,

Li Zhao,

Yuelin J. Zhu,

Mark C. Willingham,

Jun Qi,

John A. Copland,

Paul S. Meltzer,

Sheue-yann Cheng

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2016-3771

Subject(s) - bromodomain , cancer research , cell growth , brd4 , anaplastic thyroid cancer , bet inhibitor , cell cycle , chromatin , biology , thyroid cancer , acetylation , transcription factor , cancer , gene , genetics

Recent studies showed that transcription of the MYC gene is driven by the interaction of bromodomain and extraterminal domain (BET) proteins with acetylated histones on chromatin. JQ1, a potent inhibitor that effectively disrupts the interaction of BET proteins with acetylated histones, preferentially suppresses transcription of the MYC gene. We recently reported that JQ1 decreased thyroid tumor growth and improved survival in a mouse model of anaplastic thyroid cancer (ATC) by targeting MYC transcription. The role of MYC in human ATC and whether JQ1 can effectively target MYC as a treatment modality have not been elucidated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research